Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review

American Heart Journal Plus（2024）

引用 0|浏览1

暂无评分

摘要

The FDA REMS for prasugrel consisted of passive educational materials evaluated using one-time, cross-sectional surveys.

查看译文

关键词

U.S. Food and Drug Administration,Risk evaluation and mitigation programs,Drug risks

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要